Clonal evolution of Philadelphia chromosome in acute myeloid leukemia after enasidenib treatment

Leuk Lymphoma. 2021 Dec;62(12):3035-3038. doi: 10.1080/10428194.2021.1941928. Epub 2021 Jun 21.

Authors

Lori A Ramkissoon¹, Kaitlyn Buhlinger², Angela Nichols², Catherine C Coombs^{2

3}, Matthew C Foster^{2

3}, Jonathan Galeotti¹, Kathleen Kaiser-Rogers^{1

4}, Daniel R Richardson^{2

3}, Nathan D Montgomery^{1

2}, Joshua F Zeidner^{2

3}

Affiliations

¹ Department of Pathology & Laboratory Medicine, The University of North Carolina School of Medicine, Chapel Hill, NC, USA.
² Lineberger Comprehensive Cancer Center, The University of North Carolina School of Medicine, Chapel Hill, NC, USA.
³ Division of Hematology, Department of Medicine, The University of North Carolina School of Medicine, Chapel Hill, NC, USA.
⁴ Department of Pediatrics, The University of North Carolina School of Medicine, Chapel Hill, NC, USA.

PMID: 34151687
DOI: 10.1080/10428194.2021.1941928

No abstract available

Publication types

Letter

MeSH terms

Aminopyridines
Clonal Evolution / genetics
Humans
Leukemia, Myeloid, Acute* / diagnosis
Leukemia, Myeloid, Acute* / drug therapy
Leukemia, Myeloid, Acute* / genetics
Philadelphia Chromosome*
Triazines

Substances

Aminopyridines
Triazines
enasidenib

Grants and funding

L30 CA264755/CA/NCI NIH HHS/United States